

*****STN Columbus *****

FILE 'HOMI' ENTERED AT 13:44:39 ON 31 JUL 2000

index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST ENTRY SESSION
0.15 0.15

INDEX: ADISALERTS, ADISINSIGHT, AGRICOLA,
AIDSLINE, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS,
BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA, CEN, CIN,
CONFSCI, CROPB, CROPU, DDFB, DDFU,
DGENE, DRUGB, DRUGLAUNCH,
DRUGMONOG2, ... ENTERED AT 13:44:49 ON 31 JUL
2000

57 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to
view
search error messages that display as 0* with SET DETAIL
OFF.

=> s (mercaptotripropionamide or phosphonic(X))hair and
(inhib? or depilat? or prevent?)

1 FILE BIOSIS
11 FILES SEARCHED...
1 FILE CABA
9 FILE CAPLUS
20 FILES SEARCHED...
29 FILES SEARCHED...
1 FILE EMBASE
2 FILE IFIPAT
39 FILES SEARCHED...
1 FILE MEDLINE
1 FILE SCISEARCH
52 FILES SEARCHED...
1 FILE TOXLINE
1 FILE TOXLIT
206 FILE USPATFLL
1 FILE WPIDS
56 FILES SEARCHED...

1 FILE WPINDEX

12 FILES HAVE ONE OR MORE ANSWERS, 57
FILES SEARCHED IN STNINDEX

L1 QUE (MERCAPTOTRIPROPIONAMIDE OR
PHOSPHONIC(X))HAIR AND (INHIB? OR DEPILAT? O
R PREVENT?)

=> d rank

F1 206 USPATFLL
F2 9 CAPLUS
F3 2 IFIPAT
F4 1 BIOSIS
F5 1 CABA
F6 1 EMBASE
F7 1 MEDLINE
F8 1 SCISEARCH
F9 1 TOXLINE
F10 1 TOXLIT
F11 1 WPIDS
F12 1 WPINDEX

= file f2-11

COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST ENTRY SESSION
2.40 2.25

FILE 'CAPLUS' ENTERED AT 13:47:47 ON 31 JUL 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 13:47:47 ON 31 JUL 2000
COPYRIGHT (C) 2000 IFI CLAIMS(R) Patent Services
(IFI)

FILE 'BIOSIS' ENTERED AT 13:47:47 ON 31 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'CABA' ENTERED AT 13:47:47 ON 31 JUL 2000
COPYRIGHT (C) 2000 CAB INTERNATIONAL (CABI)

FILE 'EMBASE' ENTERED AT 13:47:47 ON 31 JUL 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights
reserved.

FILE 'MEDLINE' ENTERED AT 13:47:47 ON 31 JUL
2000

FILE 'SCISEARCH' ENTERED AT 13:47:47 ON 31 JUL
2000
COPYRIGHT (C) 2000 Institute for Scientific Information
(ISI) (R)

FILE 'TOXLINE' ENTERED AT 13:47:47 ON 31 JUL
2000

FILE 'TOXLIT' ENTERED AT 13:47:47 ON 31 JUL 2000
FILE 'WPIDS' ENTERED AT 13:47:47 ON 31 JUL 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

=> s 11

6 FILES SEARCHED...
L2 19 L1

=> dup rem 12

PROCESSING COMPLETED FOR L2
L3 12 DUPLICATES REMOVED
ANSWERS '1-9' FROM FILE CAPLUS
ANSWERS '10-11' FROM FILE IFIPAT
ANSWER '12' FROM FILE WPIDS

=> d bib ab 1-12

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2000
ACS DUPLICATE 1
AN 1992:486991 CAPLUS
DN 117:86991

T1 Production of the phytoalexin glyceollin I by soybean
roots in response to
symbiotic and pathogenic infection
AU Schmidt, Petra E.; Parniske, M.; Werner, D
CS Fachbereich Biol., Philipps-Universität Marburg, Germany
SO Bot. Acta (1992), 105(1), 18-25
CODEN: BOACEJ; ISSN: 0932-8629

DT Journal
LA English

AB The amt. of the phytoalexin glyceollin I (I) in root
exudate and root

hairs of individual seedlings of Glycine max was

- analyzed using a RJA. *Bradyrhizobium japonicum* 110spc4, which is able to form N fixing nodules with this plant, caused an increase of lincoc 50-fold in I levels in root exudate relative to uninfected control seedlings. Max. I levels were reached within 10 h of incubation. Elevated I levels were also obsd after incubation of soybean roots in sterile bacterial supernatant, a suspension of autoclaved bacteria or the supernatant from broken cells of *B. japonicum*. Increased I prodn. is not due to the process of active root ***hair*** penetration by the microsymbiont since living bacterial cells are not necessary for the induction. The obsd. I prodn. in *japonicum* is several times lower than that after pathogenic infection. Infection with zoospores of the phytopathogenic oomycete, *Phytophthora megasperma* f. sp. *glyciniae* race 1, leads within 20 h to an accumulation of 7 nmol I seedling in the root exudate of the compatible cultivar Kenwood and 48 nmol -I seedlings in that of the incompatible cultivar Maple Arrow. Apparently, phytoalexins are implicated in detn. of compatibility in pathogenic interactions. Crude cell exts. of different symbiotic bacteria (*B. japonicum* 110spc4, R. meliloti 2011, R. leguminosarum PRE 8, *Sinorhizobium fredii* HH 103) were found to induce different amts. of I in the root exudate. The obsd. I levels could not be correlated with the ability of these rhizobial strains to nodulate soybean. ***inhibition*** of flavonoid and phytoalexin synthesis by (R)-(1-amino-2-phenylethyl) ***phosphonic*** acid (APEP), a specific ***inhibitor*** of the phenylalanine-ammonia-lyase (PAL), during the first 20 h of the symbiotic interaction dramatically decreased the no. of nodules formed in root regions that had been in contact with the ***inhibitor***. This effect was obsd. at concns. that
- ***inhibited*** neither bacterial nor plant growth. The implications of these findings for the process of nodule initiation are discussed.
- I3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 2
AN 1986:564623 CAPLUS
DN 105:164623
TI Amelioration of cisplatin-induced ototoxicity by fosfomycin
AU Schweitzer, Vanessa G.; Dolan, David F.; Davidson Thomas, Abrams, Gerald E.; Snyder, Ronald CS Dep. Otolaryngol. Head Neck Surg., Henry Ford Hosp., Detroit, MI, 48202, USA
SO Laryngoscope (1986), 96(9, pt. 1), 948-58
CODEN: LARYA8; ISSN: 0023-852X
DT Journal
LA English
AB The continued chemotherapeutic application of cisplatin [15663-27-1] necessitates redn. of its dose-limiting toxicity without decreasing its tumoricidal effect. This research project evaluated the efficacy of fosfomycin [23155-02-4], a ***phosphonic*** acid antibiotic, in decreasing or ameliorating the ototoxicity (high-frequency sensorineural hearing loss) and nephrotoxicity (renal tubular necrosis and interstitial nephritis) of cisplatin. The efficacy of fosfomycin in blocking Pt-induced toxicity in the guinea pig was evaluated histol. and functionally using cyocochleog. and light microscopy of the organ of Corti and the auditory brain stem evoked response (ABR), and light microscopy of renal corticomedullary tissues, small bowel, liver, lung, and peripheral nerve. The results demonstrate that fosfomycin ameliorates the acute renal tubular necrosis and interstitial nephritis and markedly ***inhibits*** the elevation of ABR thresholds and simultaneous outer ***hair*** cell loss that can result from cisplatin administration.
- Fosfomycin should be considered a potential antidote for the dose-limiting ototoxicity and nephrotoxicity of cisplatin chemotherapy.
- I3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2000 ACS
AN 2000:401835 CAPLUS
DN 133:43508
TI Thienopyran derivatives with activity as potassium channel activators and their use as antihypertensives, antiasthmatics, and hair growth modulators
IN Esch, Peter; Rovinsky, Franz; Towart, Robertson; Christoph, Thomas; Hartmann, Michael; Kealey, George Terence Evelyn PA Cambridge Bioclinical Limited, UK
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE
PI WO 2000/34287 A2 20000615 WO
1999-GB4037 19991203
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, IU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PR: AI GB 1998:26830 19981204
GB 1999:9792 19990428
OS MARPAT 133:43508
AB Novel thienopyran compds. I-III [X H or electron-withdrawing group: Y - spiro fusion with an (un)substituted, unsatd. or monounsatd., alicyclic or heterocyclic ring; Z = H, OH, or alkoxy] compds. having

6 analogues

structures based on IV and V [A, D = 2-oxopyrrolidino, 2,5-dihydro-3,4-dimethyl-1-oxo-2-thienyl, and analogs], and addnl. related

compds. are disclosed. The compds. are potassium

channel activators, and

are particularly useful as hair growth modulators. The

compds. are also

useful as anti-hypertensive agents and for asthma

treatment. In

particular, one group of the compds. has a heterocyclic

ring

spiro-connected at the 7-position of the thienopyran ring

structure. For

instance, the thienopyran deriv. VI (prepn. given)

underwent a sequence

of: (1) bromination in aq. DMSO to give a trans

bromohydrin (86%); (2)

redn. of the bromide with Bu₃SnH to give the alc. (90%);

(3) oxidn. of the

alc. to a ketone with PCC (79%); (4) conversion of the

ketone to the

thione analog with Lawesson's reagent (100%), and (5)

Dieckmann reaction

of the thione with 2,3-dimethyl-1,3-butadiene (69%), to

give title compd.

VII. In a cell growth potentiation assay for prediction of

hair growth

stimulation, VII at 100 μ M showed an activity of

271% vs. minoxidil.

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 2000-53374 CAPLUS

DN 132:102860

TI ***Inhibitors*** of proteasomal activity for

stimulating bone and hair

growth

IN Mundy, Gregory R., Garrett, I. Ross, Rossini, G.

PA Osteoscreen, USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN/CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 200002548 A2 20000120 WO

1999-US15533 19990709

W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ,

EE, GE, HU, IL, IN,

IS, JP, KP, KR, LC, LK, LR, LT, LV, MD, MG,

MK, MN, MX, NO, NZ

PL, RO, SD, SG, SI, SK, TR, TT, US, UZ, VN, AM,

AZ, BY, KG, KZ,

MD, RU, TJ, TM

RW, GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW,

AT, BE, CH, CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,

BE, BJ, CF, CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PR-AI US 1998-113947 19980710

AB Compds. that ***inhibit*** the activity of

NF- κ B or

inhibit the activity of the proteasome or both

promote bone

formation and hair growth and are thus useful in treating

osteoporosis,

bone fracture or deficiency, primary or secondary

hyperparathyroidism,

periodontal disease or defect, metastatic bone disease,

osteolytic bone

disease, post-plastic surgery, post-prosthetic joint surgery,

and

post-dental implantation. They also stimulate the prodn.

of hair

follicles and are thus useful in stimulating hair growth,

including hair

d, in subject where this is desirable.

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 1997-299172 CAPLUS

DN 126:282554

TI Skin and hair sunscreens containing an iron chelator

IN Simon, Pascal; Gagnebien, Didier

PA L'Oreal S. A., Fr.

SO Can. Pat. Appl., 26 pp.

CODEN: CPXXEB

DT Patent

LA French

FAN/CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI CA 2181731 AA 19970121 CA

1996-2181731 19960719

FR 2736825 A1 19970124 FR 1995-8817

19950720

FR 2736825 B1 19970822

EP 770377 A1 19970502 EP 1996-401356

19960620

EP 770377 B1 19981028

R: DE, ES, FR, GB, IT

ES 2126367 T3 19990316 ES 1996-401356

19960620

AU 9656240 A1 19970213 AU 1996-56240

19960701

AU 677556 B2 19970424

US 5776472 A 19980707 US 1996-685913

19960722

PR-AI FR 1995-8817 19950720

OS MARPAT 126:282554

AB Skin and hair sunscreens contain a UV-A filtering agent

and an iron

chelator for the protection of the skin. A sunscreen cream

contained Me

glucose stearate 3.00, stearic acid 0.7, vaseline oil 5.00,

isostearyl

isostearate 5.00, cyclomethicone 5.00, sucrose stearate

1.3, glycerin

2.00, hexylene glycol 4.00, Dequest 2046 (iron chelator)

2.00, 33% aq

terephthalylidene dicamphorsulfonic acid 2.5,

triethanolamine 0.5, and

water q.s. 100%.

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 1996-546085 CAPLUS

DN 125:196374

TI Preparation of 2-amino-3- ***mercaptopropionamide***

derivatives for

hair treatment composition

IN Kyomine, Akira, Nishizawa, Yoshinori, Ezure, Mikako;

Kondo, Masahiro

PA Kao Corp. Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXCAF

DT Patent

LA Japanese

FAN/CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI JP 08157448 A2 19960618 JP 1994-300566

19941205

OS MARPAT 125:196374

AB The title cysteinamide derivs. (R)-, (S)-, or

(RS)-HSC₂H₄CH(NH₂)CONHR₁ (R₁

= C1-2 linear or branched alkyl substituted with 1-4 HO

groups or C1-4

alkoxy groups), which are useful as reducing agents for hair preps, such as primary agents for wave-setting or straightening curly hair.

pre-treatment agents for dyeing hair, oxidative hair dyes, or ***deplatory*** agents, are prepd. This compds. give little damage to

hair, reduced odor and flaking, excellent waving effect, and long-lasting

wave and are safely used. Thus, 82.5 g

monoethanolamine and 25.0 g Et

L-cysteinate hydrochloride were placed in a reaction bath, heated at 7-5

mmHg and room temp. for 1 h, and treated with a soln. of 5.4 g NaOH in 20

H₂O under cooling. Excess monoethanolamine was distd. off at 7-5 mmHg and

58-71 degree, to give an oil, which was treated with 200 mL ethanol.

refluxed, filtered to remove insol. NaCl, cooled, and filtered to remove

pptd. crystals to give 45%

(R)-HSC12CH(NH₂)CONHCH₂CH₂OH.

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 1996:315324 CAPLUS

DN 124:352330

TI Anti-dandruff hair rinse containing cationic germicide, quaternary

ammonium conditioner, and metal chelator

IN Hioki, Yuichi; Moriama, Tadashi; Tamura, Yoshinori; Okamoto, Juri;

Takeshige, Yuichi

PA Kao Corp., Japan

SO Ger. Offen., 13 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN CNT 1

PATENT NO. KIND DATE APPLICATION

NO. DATE

PI DE 19536420 A1 19960411 DE

1995:19536420 19950929

JP 08099841 A2 19960416 JP 1994:239981

19941004

CN 1126585 A 19960717 CN 1995:117383

19950929

PR:AI JP 1994:239981 19941004

OS MARPAT 124:352330

AB A hair rinse contg. (a) an alkylbenzyltrimethylammonium germicide, (b) a quaternary ammonium-type cationic polymer or cationic surfactant as

conditioner, and (c) a chelating agent in a molar ratio to the other 2

components of, g:oreq.0.5 shows good conditioning,

anti-dandruff,

antipruritic, and deodorant activity even in the presence of

anionic

surfactants. Thus, a hair rinse was prepd. contg. (2-

dodecylhexadecyltrimethylammonium chloride 1.5,

benzalkonium chloride

1.0, di-Na EDTA 2.0, cetostearyl alc. 3.0, liq. paraffin

1.0,

dimethylpolysiloxane 1.0, hydroxyethylcellulose 0.5,

methylparaben 0.5,

perfume 0.4, and water to 100.0%.

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 1994:143672 CAPLUS

DN 120:143672

TI Composition for treating keratinous fibers containing metal compounds and

acids

IN Hirano, Yuji; Kure, Naohisa

PA Kao Corp., Japan

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN CNT 1

PATENT NO. KIND DATE APPLICATION

NO. DATE

PI WO 9400099 A1 19940106 WO 1993-JP868

19930625

W: US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE

JP 06009347 A2 19940118 JP 1992:170911

19920629

EP 601163 A1 19940615 EP 1993:013584

19930625

EP 601163 B1 19960320

R: DE, FR, GB

US 5472697 A 19951205 US 1994:182122

19940203

PR:AI JP 1992:170911 19920629

WO 1993-JP868 19930625

AB A compn. for treating keratinous fibers comprises: (a) a first agent

contg. a metal ion, (b) a second agent contg. an org. or

inorg. compd.

which is capable of readily permeating into the keratinous

fibers and can

form water-insol. or sparingly sol. complex together with

the metal ion of

component (a), and an org. compd. which cannot readily

permeate into the

keratinous fibers, and which reacts with the metal ion of

component (a) to

form a water-sol. complex. When the compn. is used for

treating

keratinous fibers, it allows water-insol. or sparingly sol.

complex

products to deposit inside the keratinous fibers while

preventing

them from depositing on the surface of the keratinous

fibers. Because of

this mechanism, the present compn. is capable of

imparting sufficient

firmness and elasticity to keratinous fibers without

inducing any

objectionable rough or frictional feel to the touch of the

hair. For

example, a first agent contained hydroxyethyl cellulose

1.3, CaCl₂ 1.5%,

and water balance and a second agent contained

hydroxyethyl cellulose 1.3,

oxalic acid 2.0, 1-hydroxyethylidene-1,1-disulfonic acid

1.0%, arginine

q.s., and water balance.

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2000

ACS

AN 1971:532922 CAPLUS

DN 75:132922

TI Aminopolysphonic acids and polyphosphonic acids

and their derivatives

for the protection of hair

IN Berth, Peter; Reese, Guenter

PA Therachemie Chemisch Therapeutische G.m.b.H.

SO U.S., 3 pp.

CODEN: USXXAM

DT Patent

LA English

FAN CNT 1

PATENT NO. KIND DATE APPLICATION

NO. DATE

PI US 3542918 A 19701124 US 1966-586955
 19661017
 NI 6615210 A 19670525 NI 1966-15210
 19661027
 NI 160161 B 19790515
 BE 689986 A 19670522 BF 1966-89986
 19661121
 IT 1013002 A 19770330 IT 1966-43047
 19661122
 ES 333706 A2 19680101 ES 1966-333706
 19661123
 CH 482444 A 19691215 CH 1966-482444
 19661123
 DK 116529 B 19700119 DK 1966-6068
 19661123
 NO 122856 B 19710823 NO 1966-165707
 FI 45213 B 19711231 FI 1966-3108
 19661124
 SE 343475 B 19720313 SE 1966-16110
 19661124
 PR AI DE 1965-129843 19651124
 AB Damage to human hair during bleaching or dyeing was
 prevented by
 using 0.01-10% of an aminopolysphosphonic acid or deriv.
 alone or in
 combination with a polysphosphonic acid. For example, a
 6 H2O2 bleaching
 soln. (pH 10) was mixed with 0.1%
 aminotris(methylenephosphonic acid) (I)
 or a mixt. of 0.1% of equal parts ethanol-1,
 1-diphosphonic acid and I and
 applied to human hair, and the hair developed a high gloss
 and sheen, with
 little damage. Other P compds. used were
 ethylenediaminetetrakis(methylene
 phosphonic acid), Na, K, or monoethanolamine salt,
 monoethyl
 aminoethane-1, 1-diphosphonate,
 aminotris(methylenephosphonic acid) or
 NH4+ salt, aminotris(isopropylmethylene phosphonic acid) or I
 NH4+ salt.

L3 ANSWER 10 OF 12 IFIPAT COPYRIGHT 2000 IFI
 AN 2699838 IFIPAT:IFIUDB:IFICDB
 TI COMBINED TWO-PART REDUCING
 AGENT HUMECTANT SHAVING SYSTEM FOR
 IMPROVED
 SHAVING COMFORT, BREAKING DISULFIDE
 BONDS, TOILETRIES
 INF Stife, Charles W., New Market, MD

Stoner, Karla L., Frederick, MD
 IN Stife Charles W., Stoner Karla L.
 PAF The Gillette Company, Boston, MA
 PA Gillette Co The (34696)
 ENNAM Page, Thurman K
 AG Williams, Stephan P
 PI US 5500210 19960319 (CITED IN 002 LATER
 PATENTS)
 AI US 1994-247915 19940523
 XPD 23 May 2014
 FI US 5500210 19960319
 DT UTILITY
 FS CHEMICAL
 MRN 007091 MFN: 0351
 CLM 10
 AB The present invention relates to a method of improving
 shaving comfort by
 softening the hair to be shaved so as to reduce the cutting
 force
 required to cut it. The novel method comprises carrying
 out the following
 sequential steps: (a) contacting an area of hair to be
 shaved with a
 reducing agent that breaks disulfide linkages in hair; (b)
 contacting the
 area of hair treated in step (a) with a humectant and
 allowing it to dry
 or partially dry; (c) contacting the area treated in step (b)
 with water
 to hydrate the hair; and (d) shaving the hydrated hair of
 step (c).

L3 ANSWER 11 OF 12 IFIPAT COPYRIGHT 2000 IFI
 AN 0252997 IFIPAT:IFIUDB:IFICDB
 TI PHOSPHONIC ACID DERIVATIVES FOR
 PROTECTION OF HAIR FROM DAMAGE IN
 BLEACHING AND DYEING THE SAME
 IN BERTH PETER (DE); REESE GUNTER (DE)
 PA THERACHEMIE CHEMISCH THERAPEUTISCHE
 GESELLSCHAFT MBH GER (84160)
 PI US 3202579 19650824 (CITED IN 018 LATER
 PATENTS)
 AI US 1963-310165 19630919
 XPD 24 Aug 1982
 PRAI DE 1963-T23551 19630302
 FI US 3202579 19650824
 FR 1393604
 DT UTILITY
 FS CHEMICAL
 OS CA 63-4092

L3 ANSWER 12 OF 12 WPIDS COPYRIGHT 2000
 DFRWENT INFORMATION LTD
 AN 1994-147833 [18] WPIDS
 DNC C1994-067894
 TI ***Hair*** washing compsn for time-lapse
 colouration
 prevention - contg. anionic surfactant(s), alkanol
 amide(s), amido
 amine type amphoteric surfactant(s), di
 phosphonic acid(s), and
 l-menthol and or dl-menthol.
 DC A96 D21 E19
 PA (SUNZ) SUNSTAR CHEM IND
 CYC 1
 PI JP 06092826 A 19940405 (199418)* 6p
 ADT JP 06092826 A JP 1992-268087 19920909
 PRAI JP 1992-268087 19920909
 AB JP 06092826 A UPAB: 19940622
 The compsn. contains (A) 1-20 wt % of an anionic
 surfactant(s) of formula
 R1-O-(CH2CH2O)n-SO3M (I), (B) 0.1-10 wt % of an
 alkanol amide(s) of
 formula (II), (C) 0.1-2.0 wt % of an amido amine type
 amphoteric
 surfactant(s) of formula (III), (D) 0.001-1 wt % of
 diphosphonic acid(s)
 of formula (IV), (E) 0.01-3 wt % of l- and or dl-menthol
 and (F) 0.01-1
 wt % of an organic acid(s). R1 is 8-20 C alkyl or alkenyl;
 n is 0-5; and M
 is NH4 or cation derived from an alkanolamine. R2 is
 7-21C alkyl or
 alkenyl. R3 and R5 are 7-19C alkyl or alkenyl; R4 and
 R6 are -CH2COOM1 or
 -CH2CH2COOM1; R7 is H, -CH2COOM1 or
 -CH2CH2COOM1; and M1 is H, alkali
 metal or cation derived from an alkanolamine. M2 - M5
 are H or alkali
 metal.
 USE - The compsn. does not cause time-lapse
 colouration.
 Dwg.0 0
 => log y
 COST IN U.S. DOLLARS SINCE FILE
 TOTAL ENTRY SESSION
 FULL ESTIMATED COST 76.09

78.49

DISCOUNT AMOUNTS (FOR QUALIFYING
ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CASH SUBSCRIBER PRICE -5.01
-5.01

STN INTERNATIONAL LOGOFF AT 13:57:11 ON 31
JUL 2000